Disease-modifying drugs – molecular and clinical aspects

Stefan Mackiewicz

eISSN: 2084-9834
ISSN: 0034-6233

Reumatologia/Rheumatology

Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

5/2010
vol. 48

Send email

Copy url:

abstract:

Editorial

Disease-modifying drugs – molecular and clinical aspects

Stefan Mackiewicz

Reumatologia 2010; 48, 5: 289–292

Online publish date: 2010/11/16

View full text Get citation

Disease-modifying antirheumatic drugs (DMARDs) are involved in the control of inflammation. A great number of mechanisms take part in the treatment procedures undertaken in rheumatoid arthritis and allied conditions. Inhibition of biological hyperreactivity is the most important phenomenon operating in the signal transduction cascade (cells, genes, molecules), following DMARDs therapy. Clinical remission can be achieved in approximately 50% of treated patients.

keywords:

disease-modifying drugs, regulatory mechanism, signal transduction cascade (cells–genes–molecules)

EVENTS/KONFERENCJE

BOOKS/KSIĄŻKI